
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under Rule 14a-12


Mind Medicine (MindMed) Inc.
(Name of Registrant as Specified In Its Charter)

N/A
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required
 - Fee paid previously with preliminary materials
 - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-
-

On May 2, 2023, Mind Medicine (MindMed) Inc. (the “Company”) launched a website in connection with the Company’s 2023 Annual General Meeting of Shareholders. A copy of the materials (other than those previously filed under cover of Schedule 14A) on the website can be found below.



Disclaimer

Disclaimer

This website is provided merely as information and is not intended as a solicitation or offering of securities in any jurisdiction and the information contained herein in no way should be construed or interpreted as such. No securities commission or other regulatory authority in the United States of America, Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warrant is made by Mind Medicine (MindMed) Inc. (the "Company" or "MindMed") to that effect. The information on this website is not intended to modify, qualify, supplement or amend information disclosed under corporate and securities legislation of any jurisdiction applicable to MindMed and should not be used for the purpose of making investment decisions concerning MindMed's securities. This website is the exclusive property of MindMed and may not be reproduced or distributed, in whole or in part, without the express prior written consent of the Company.

THE INFORMATION AND MATERIALS CONTAINED IN THIS WEBSITE ARE PROVIDED "AS IS" WITHOUT ANY EXPRESS OR IMPLIED WARRANTY OF ANY KIND, INCLUDING WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF INTELLECTUAL PROPERTY, OR FITNESS FOR ANY PARTICULAR PURPOSE. IN NO EVENT SHALL THE COMPANY BE LIABLE FOR ANY DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, DAMAGES DUE TO LOSS OF PROFITS OR BUSINESS INTERRUPTION) OR DUE TO THE USE OF OR INABILITY TO USE THE MATERIALS.

In using this website, you agree that MindMed shall not be liable for any damages whatsoever (including indirect, incidental, special, punitive or consequential damages and loss of profits, opportunities or information) arising from (a) your use of or reliance on information contained on this website; (b) any inaccuracy or omission in such information or failure to keep the information current; (c) use of any third party web sites linked or referred to in this website; (d) any delays, inaccuracies or errors in, or in the transmission of, any stock price quotes or historical price data; (e) any internet software used in connection with this website or computer viruses or other destructive programs encountered as a result of using this website; and (f) any other matter connected with the website, even if MindMed is made aware of the possibility of such claims, damages or losses.

Although considerable care has been taken in preparing and maintaining the information and materials contained on this website, they are provided on an "as is" basis, without warranty of any kind, either express or implied, with respect to the accuracy or completeness of the information. Unless otherwise indicated, all information posted on this website is current only as of the date of the document that contains the information, if indicated, or the date on which the document is posted, whichever is earlier. MindMed may at any time make changes to the information at this website without prior notice. You should always ensure that you are referring to the most current information available on this website.

Privacy Policy

MindMed is committed to controlling the collection, use and disclosure of personal information. A copy of MindMed's Privacy Policy can be accessed at the bottom of the webpage. If you have any concerns relating to the privacy or confidentiality of this website, please contact MindMed's Privacy Officer at privacyofficer@mmed.global.

Cautionary Notes and Forward-Looking Statements

Certain statements on this website related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Undue reliance should not be placed on forward-looking information, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. There can be no assurance that the plans, intentions or expectations upon which forward-looking statements are based will in fact be realized. Forward-looking information on this website includes, but is not limited to, statements regarding the potential benefits and development of the Company's product candidates, trials, studies and programs; the strengths and benefits of the Company's strategic plan; the Company's business plans and objectives; the ability of MindMed to achieve success consistent with management's expectations; and the expected impact and results of the Company's corporate governance practices, including of the Company's director nominees.

Forward-looking information is based on the opinions and estimates of management of the Company at the date the statements are made, as well as a number of assumptions made by, and information currently available to, the Company concerning, among other things, anticipated performance of its product candidates and programs, business prospects, strategies, regulatory developments, the development of its product candidates into effective products, the ability to produce products if approved, the approval by regulators of any products that are developed, and the non-occurrence of the risks and uncertainties outlined below or other significant events occurring outside of MindMed's normal course of business. Although management of the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.

There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows, limited operating history, incurrence of future losses; availability of additional capital; changes in market conditions; lack of product revenue; compliance with laws and regulations; changes in government policy; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry, as well as those risk factors discussed or referred to herein and the risks described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 under headings such as "Special Note Regarding Forward-Looking Statements," and "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission ("SEC") on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained on this website as a result of new information, future events, changes in expectations or otherwise.

Additional Information and Where to Find It

MindMed has filed with the SEC and Canadian securities regulatory authorities on May 1, 2023 a definitive proxy statement on Schedule 14A (the "proxy statement"), containing a form of WHITE universal proxy card, with respect to its solicitation of proxies for the annual general meeting of shareholders of MindMed on June 15, 2023 (the "Annual Meeting"). Details concerning the nominees of MindMed's Board for election at MindMed's Annual Meeting are included in the proxy statement. This website is not a substitute for the proxy statement or other document that MindMed has filed or may file with the SEC and Canadian securities regulatory authorities in connection with any solicitation by MindMed.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO AND THE ACCOMPANYING WHITE UNIVERSAL PROXY CARD) FILED BY MINDMED AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC AND CANADIAN SECURITIES REGULATORS WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MINDMED AND ANY SOLICITATION. Investors and security holders may obtain copies of these documents and other documents filed with the SEC and Canadian securities regulatory authorities by MindMed free of charge through the website maintained by the SEC at www.sec.gov or through the Company's profile on SEDAR at www.sedar.com. Copies of the documents filed by MindMed are also available free of charge by accessing MindMed's website at www.mindmed.co.

Participants in the Solicitation


This website is neither a solicitation of a proxy or consent nor a substitute for any proxy statement or other filings that may be made with the SEC and Canadian securities regulatory authorities. Nonetheless, MindMed, its directors and executive officers and other members of management and employees may be deemed under U.S. securities laws and Canadian securities laws to be participants in the solicitation of proxies with respect to a solicitation by MindMed. Information about MindMed's executive officers and directors and other participants in the solicitation, including their respective interests, by security holders or otherwise, is available in the proxy statement. To the extent holdings of MindMed securities reported in the proxy statement for the Annual Meeting have changed, such changes have been or will be reflected on Statements of Change in Ownership on Forms 3, 4 or 5 filed with the SEC and if applicable, on the System for Electronic Disclosure by Insiders (SEDI) in accordance with insider reporting requirements of Canadian securities laws. These documents are or will be available free of charge at the SEC's website at www.sec.gov and either through the Company's profile on SEDAR at www.sedar.com or updated filings on SEDI at www.sedi.ca.

Third-Party Information

This website may contain or refer to news, commentary and other information relating to the Company generated by, or sourced from, persons or companies that are not affiliated with the Company. The Company has neither sought nor obtained permission to use or quote such third-party information, including, without limitation, information generated by FCM MM HOLDINGS, LLC ("FCM") or its affiliates. The Company has not assisted in the preparation of any third-party information, including, without limitation, information generated by FCM or its affiliates. Any statement or information that is obtained or derived from statements made or published by a third party should not be viewed as indicating the support of such third party for any view expressed on this website.

Not Responsible for Linked Websites

This website provides links and references to several third party websites for your convenience only and the inclusion of these links does not imply that MindMed monitors or endorses these websites. MindMed has no control over information at sites hyperlinked or referred to in this website other than other MindMed websites. The links and references to third party websites are being provided for the convenience of the users of this website and MindMed does not endorse and is not responsible or liable for the content, nature or reliability of any linked or referenced website or any link contained in a linked or referenced third party website. MindMed takes no responsibility for monitoring, updating, supplementing or correcting any information on any linked or referenced third party website and makes no representation or warranties regarding such information. Please be aware that in linking or going to these third party websites, you are leaving the MindMed website and that MindMed is not responsible for the content of any such site.



[Home](#) [Our Nominees](#) [How To Vote](#) [Important Materials](#) [Contact Us](#)



[DISCLAIMER](#)

[PRIVACY POLICY](#)

Protect MindMed

MindMed is successfully executing our clearly defined strategy to bring transformative therapies to market and generate sustainable, long-term shareholder value.

[OUR NOMINEES](#)

[HOW TO VOTE](#)

 [Read Our Letter to Shareholders](#)

MindMed has seen significant positive momentum and 2023 is a pivotal period for the Company, with two key clinical readouts on our primary drug candidates expected later this year.

Our Board's six highly qualified nominees have the right mix of experience and expertise to oversee the execution of MindMed's strategy and position the Company for sustained value creation.

FCM is waging a proxy contest to take control of the Company despite only owning a small percentage of our outstanding shares and failing to provide any realistic strategic plan for MindMed.

FCM's candidates lack the experience to be additive to our Board and, if elected, would put MindMed's strategy and shareholders' investments at serious risk and cause permanent value destruction.





VOTE ON THE WHITE PROXY CARD TODAY FOR ALL OF THE COMPANY'S NOMINEES AND WITHHOLD ON FCM'S NOMINEES TO PROTECT MINDMED.

[MEET OUR BOARD NOMINEES](#)

MYTH VS FACT

Despite FCM's misguided statements, the facts are clear:

 <p>MindMed is Successfully Executing on Our Strategy to Develop Our Diversified Pipeline of Clinical Programs</p> <p>Recent clinical trial milestones demonstrate MindMed's momentum across its R&D pipeline, with two key clinical readouts anticipated later this year.</p>	 <p>MindMed Has a Proven Track Record of Proactive Director Refreshment</p> <p>Our slate of directors represents a 100% refreshment of the Board since Robert Barrow became interim CEO in June 2021.</p>	 <p>Our Board has the Right Mix of Experience and Backgrounds to Lead MindMed</p> <p>Our Board has the necessary drug development and commercialization, financial management and capital allocation, and corporate governance and compliance experience to oversee MindMed's strategy.</p>
 <p>FCM Does Not Understand the Business</p>	 <p>FCM Has Not Made a Case for Representation on the Board, Let</p>	 <p>FCM's Nominees Do Not Have Additive Backgrounds or Experience</p>

The ideas FCM has raised demonstrate an ignorance of the FDA drug approval process applicable to major market psychiatric disorders and ignorance of the capital allocation and financing needs of a company at MindMed's growth stage and would destroy value for shareholders.

Alone Control

If all of its nominees are elected, FCM would control the Company and its \$100+ million in cash on hand despite only owning a small percentage of our outstanding shares and failing to provide any realistic strategic plan for MindMed. Giving FCM any representation on the Board would endanger the Company's current strategy and team at a pivotal period, putting shareholders' investment at risk.

FCM's nominees lack the relevant experience overseeing clinical, regulatory and go-to-market strategies for MindMed's field of drug candidates as well as the relevant public company board experience and expertise needed in other key areas such as capital raising.



Vote TODAY on the WHITE proxy card FOR all six of the Board's nominees, FOR the other proposals recommended by MindMed, and WITHHOLD on FCM's nominees.

[HOW TO VOTE](#)



Important Materials

- MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing Strategy**
MAY 2, 2023
- MindMed's Letter to Shareholders**
MAY 2, 2023
- MindMed Definitive Proxy Statement**
MAY 1, 2023

[VIEW ALL](#)



Stay Updated

Fill out the fields to stay updated

Enter your name

Enter your email

[SUBMIT](#)



[Home](#) [Our Nominees](#) [How To Vote](#) [Important Materials](#) [Contact Us](#)



Our Nominees

[ROBERT BARROW](#)
[SUZANNE BRUHN](#)
[ROGER CRYSTAL](#)
[DAVID GRYSKA](#)
[ANDREAS KREBS](#)
[CAROL VALLONE](#)


Robert Barrow

Robert Barrow possesses deep knowledge of the Company and extensive experience in clinical pharmacology and drug development programs in a variety of disease areas, as well as financial expertise – all of which are essential to our Board.

- ✓ Accomplished pharmaceutical executive
- ✓ Drug development and commercialization experience
- ✓ Financial expertise

Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Prior to his current position as Chief Executive Officer, he served as MindMed's Chief Development Officer and Senior Vice President of Development. Mr. Barrow previously served as Director of Drug Development & Discovery at the Usona Institute, where he oversaw the organization's research and development activities, leading the clinical development and gaining a breakthrough designation for its psilocybin program in major depressive disorder. Prior to joining the Usona Institute, Mr. Barrow served as Chief Operating Officer and a director of Olatec Therapeutics LLC, a private, clinical-stage biopharmaceutical company, where he oversaw the execution of early- and late-stage development programs in the fields of analgesics, rheumatology, immunology and cardiovascular disease. Mr. Barrow has also served as both a technical and business adviser to numerous pharmaceutical organizations ranging from startups to Fortune 500 companies.

He holds a Masters degree in Pharmacology from Ohio State University and a Bachelor of Science degree in Finance from Wake Forest University, where he graduated *summa cum laude*. Mr. Barrow is also a CFA charterholder.



Suzanne Bruhn, Ph.D

Suzanne Bruhn, Ph.D possesses significant experience as chief executive officer of several biotech companies and as a member of the board of directors of several public companies in the life sciences industry, which provide her with the relevant public company governance experience and industry knowledge that are necessary to our Board.

- ✓ Public company CEO experience
- ✓ Biotechnology, pharmaceutical and therapeutics industry expertise
- ✓ Board and corporate governance expertise

Dr. Bruhn is an accomplished life sciences executive and brings expertise in R&D, commercialization, and executive leadership to this role. She is the President and Chief Executive Officer of Taki Therapeutics, a privately held biotechnology company. Prior to that, Dr. Bruhn served as President and Chief Executive Officer of Proclara Biosciences, Inc., a private, clinical-stage biotechnology company, and as President and Chief Executive of Promedior, Inc., a private, clinical-stage biotechnology company. Prior to Promedior, she spent 13 years at Shire Human Genetic Therapies (HGT), a division of Shire PLC, specializing in the development and commercialization of treatments for orphan diseases, where she held a series of positions of increasing responsibility before serving as Senior Vice President of global regulatory affairs. During her tenure at Shire/HGT, Dr. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management, and for global regulatory affairs. Prior to her time at Shire, Dr. Bruhn held various positions at Cytotherapeutics, Inc., a biotechnology company. Dr. Bruhn currently sits on the board of directors of Pliant Therapeutics, Inc. (NASDAQ: PLRX), Traver Therapeutics, Inc. (NASDAQ: TVTX) and Vigil Neuroscience (NASDAQ: VIGL). She has served on the boards of directors of several publicly traded therapeutics and pharmaceutical companies, including: Avalo Therapeutics, Inc. (fka Cerecor Inc.) (NASDAQ: AVTX); Aegle BioTherapeutics, Inc. (NASDAQ: AGLE); and Raptor Pharmaceuticals Corp., (NASDAQ: RPTP), until its acquisition by Horizon Pharma plc.

Dr. Bruhn holds a Bachelor of Science in Chemistry from Iowa State University, a Doctor of Philosophy in Chemistry from the Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.



Roger Crystal, M.D.



Roger Crystal, M.D. possesses extensive experience leading a pharmaceutical company as its chief executive officer. His background and training as a medical doctor and his strong background in clinical research, product development and commercialization make him qualified to serve on our Board.

- ✓ Public company CEO experience
- ✓ Accomplished pharmaceutical executive
- ✓ Biotechnology, pharmaceutical and therapeutics industry expertise

Dr. Crystal brings more than 15 years of experience as a healthcare business executive and clinician. Until its recent acquisition by Indivior PLC, Dr. Crystal was the President, Chief Executive Officer and Director for Opiant Pharmaceuticals, Inc., a publicly traded pharmaceutical company (NASDAQ: OPNT). Dr. Crystal led Opiant Pharmaceutical Inc.'s development of NARCAN® Nasal Spray for opioid overdose, which led to U.S. Food and Drug Administration approval and is the lead inventor on the product's patents. Dr. Crystal previously served as the Chief Business Officer for ImaginAb, a venture capital-backed biotechnology company. He began his business career with roles at Goldman Sachs, A.T. Kearney, and GE Healthcare. Prior to his business career, Dr. Crystal worked for several years as a surgeon, specializing in ear, nose, and throat, head and neck surgery at leading institutions including Imperial College Healthcare, London and was awarded Membership of The Royal College of Surgeons of England (MRCS).

Dr. Crystal holds a Bachelor of Medical Sciences in Physiology and a Doctor of Medicine from the University of Birmingham, UK and a Master of Business Administration from the London Business School.



David Gryska

David Gryska is an experienced biopharmaceutical company chief financial officer and director. His extensive audit and financial expertise make him an asset to our Board.

- ✓ S&P 500 CFO experience
- ✓ Audit, compliance and capital allocation expertise
- ✓ Board and corporate governance expertise

Mr. Gryska possesses decades of experience as a c-suite executive and director at a number of leading public biopharmaceutical companies. He most recently served as Executive Vice President and Chief Financial Officer of Incyte Corporation, a biopharmaceutical company (NASDAQ: INCY). Additionally, Mr. Gryska served as Chief Operating Officer of Myrexis, Inc., a biopharmaceutical company as well as Senior Vice President and Chief Financial Officer of Celgene Corporation, a former publicly traded biopharmaceutical company acquired by Bristol-Myers Squibb Company. Previously, Mr. Gryska served at Scios Inc., a former publicly traded biopharmaceutical company acquired by Johnson & Johnson, as Senior Vice President and Chief Financial Officer, and as Vice President of Finance and Chief Financial Officer. Mr. Gryska also served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways Corporation, a former publicly traded medical device company acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young LLP in California. Mr. Gryska currently serves on the boards of directors of biopharmaceutical companies Seagen, Inc. (NASDAQ: SGEN) and Forte Biosciences, Inc. (NASDAQ: FRBX).

He holds a Bachelor of Arts in Accounting and Finance from Loyola University and an M.B.A. from Golden Gate University.



Andreas Krebs

Andreas Krebs possesses financial expertise, investment experience and experience as an international pharmaceutical executive – all of which are an asset to our Board.

- ✓ Accomplished pharmaceutical executive
- ✓ Financial expertise
- ✓ Board and corporate governance expertise

Mr. Krebs is an internationally experienced executive, entrepreneur and best-selling author who serves as Vice Chair of the Board. Mr. Krebs heads the family-owned investment company, Longfield Invest, which focuses on growth companies in various industries as well as in the new economy. He has worked in seven countries across Latin America, Asia and Canada, and as President and executive board member of Wyeth Corporation in the United States. Mr. Krebs was chairman of the Supervisory Board and Shareholder Council of Merz Pharma, Frankfurt am Main, Germany and holds other board positions at private companies across various sectors and he is an Industry Advisor for the investment firm, Nordic Capital.

Mr. Krebs received degrees in Commercial Management/Business Administration of BSE Academy, State of Hessen/Germany and in-house Academy of Woelm Pharma, Eschwege, Germany.



Carol A. Vallone

Carol A. Vallone possesses financial, executive and governance expertise resulting from her service on the boards of trustees for multiple hospitals; extensive experience building and selling global companies; and experience as a director and advisor to several healthcare companies – all of which make her qualified to serve on our Board.

- ✓ CEO experience scaling global companies with successful exits
- ✓ Financial expertise and capital raises
- ✓ Board and corporate governance expertise in the healthcare industry

Ms. Vallone is a well-known business leader, former CEO, and corporate board director, with a strong track record in launching, scaling and selling global companies. She currently serves as chair of the Board of Trustees for McLean Hospital, the #1 ranked psychiatric hospital in America, according to U.S. News & World Report, and the largest psychiatric affiliate of Harvard Medical School. She also serves on the board of trustees and the finance committee of Mass General Brigham, an integrated healthcare system including five nationally ranked hospitals. Ms. Vallone serves as a board member for Cresco Labs, Inc., a publicly traded cannabis company (CSE: CL) and for Arosa, a Bain Capital Double Impact portfolio company. She is also the chair of the board of Ria Health, an SV Health investors portfolio company. She is an Industry Advisor for the investment firm, Berkshire Partners and an Advisory Board Member of the healthcare-focused venture growth firm, Longitude Capital. Ms. Vallone has served as founder and Chief Executive Officer of global e-learning companies, held management positions in leading enterprise technology companies and served on the boards of a public bank and a private-equity backed e-commerce company that went public.

Ms. Vallone holds a Bachelor of Science in Business Administration from the University of Delaware.

MindMed's Board is committed to delivering sustainable long-term value creation for all shareholders.

[HOW TO VOTE](#)



[Home](#) [Our Nominees](#) [How To Vote](#) [Important Materials](#) [Contact Us](#)



[DISCLAIMER](#)

[PRIVACY POLICY](#)

How To Vote

YOUR VOTE IS IMPORTANT! PLEASE VOTE BY:



INTERNET
Go To: www.proxyvouch.com/MNMD

- Cast your vote online
- Have your Proxy Card ready
- Follow the simple instructions to record your vote



MAIL
Mark, sign and date your Proxy Card

- Fold and return your Proxy Card in the postage-paid envelope provided



You must register to attend the meeting online and/or participate at www.proxydocs.com/MNMD

TO VOTE ACCORDING TO YOUR BOARD'S RECOMMENDATIONS, PLEASE COMPLETE YOUR PROXY CARD AS SHOWN BELOW

Mind Medicine (MindMed) Inc.
Annual General Meeting of Shareholders

If you sign and return your proxy card and vote for the proxy, you are voting your shares for the votes that will be cast at the Annual Meeting of Shareholders to elect the Board of Directors.

Please make your marks like this:

THE BOARD OF DIRECTORS RECOMMENDS A VOTE
FOR ON PROPOSALS 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 AND 17
WITHHELD ON PROPOSALS 1, 2, 3, 4, 5 AND 17

PROPOSAL	FOR	WITHHELD	AGAINST
1. Election of Directors to hold office until the 2024 annual general meeting of shareholders			
<small>While you may mark instructions with respect to any or all of the nominees, you may mark a vote "FOR" only on the nominees in blue. If you vote "FOR" more than six (6) nominees, your votes will be invalidated and not counted. You are prohibited from voting for more than six (6) nominees. If you vote "FOR" fewer than six (6) nominees, your shares will only be voted "FOR" those nominees you have marked.</small>			
FOR <input checked="" type="checkbox"/> WITHHELD <input type="checkbox"/> AGAINST <input type="checkbox"/>			
1.01 Dr. Suzanne Butler	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.02 Dr. Roger Coates	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.03 David Dwyer	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.04 Andrew Franks	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
1.05 Carol A. Graham	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
FOR <input type="checkbox"/> WITHHELD <input checked="" type="checkbox"/> AGAINST <input type="checkbox"/>			
2. To appoint PWC LLP as independent registered audit accounting firm for the Company until the close of 2024 annual general meeting of shareholders	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Approval of Financial Statements - Check the box to the right if you would like to receive the Annual Financial Statements and accompanying Management's Discussion and Analysis by mail. <input type="checkbox"/>			
Approval of Financial Statements - Check the box to the right if you would like to receive the Annual Financial Statements and accompanying Management's Discussion and Analysis by mail. <input type="checkbox"/>			

You must register to attend the meeting online and/or participate at www.proxydocs.com/MNMD

Additional Information: Mail-in instructions are provided on the reverse side of this proxy card. Please sign this proxy card in your presence or your presence by proxy. If you are a shareholder, please sign this proxy card in your presence or your presence by proxy. If you are a shareholder, please sign this proxy card in your presence or your presence by proxy. If you are a shareholder, please sign this proxy card in your presence or your presence by proxy.

SIGN HERE _____ **DATE** _____

Signature (For Internet) _____ Date _____



[Home](#) [Our Nominees](#) [How To Vote](#) [Important Materials](#) [Contact Us](#)



[DISCLAIMER](#)

[PRIVACY POLICY](#)

Important Materials

Important Materials

-  **MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing Strategy**
MAY 2, 2023
-  **MindMed's Letter to Shareholders**
MAY 2, 2023
-  **MindMed Definitive Proxy Statement**
MAY 1, 2023
-  **MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting**
APRIL 18, 2023



Contact Us

MEDIA CONTACT



Longacre Square Partners

Dan Zacchei / Joe Germani
mindmed@longacresquare.com

INVESTOR CONTACT

MORROW
SODALI

Morrow Sodali

Michael Verrechia / Eric Kamback
MNMD@investor.morrowsodali.com

STAY UPDATED

Fill out your name and email address to stay updated

SUBMIT

We Want To Hear From You

Please anonymously submit your comments or concerns using the adjacent form. We'd love to hear from you.

Note that your personal information will not be saved.

Input anonymous information here

SUBMIT



Privacy Policy

Welcome to Mind Medicine Inc. ("MindMed", "we", "us", "our"). The MindMed website exists to provide information on the company, pipeline, and research to the users ("you"). To provide this service MindMed collects some of your data, when you are using www.ProtectMindMed.com ("site"), or any MindMed website. This Privacy and Cookies Policy (the "Privacy Policy") is intended to inform you about MindMed's practices regarding the collection and use of your data that you may submit to MindMed. Please read the Privacy Policy carefully.

1. This Privacy Policy was last modified on **30 April 2023** and may be updated to reflect changes in legislation, so please review it now and then. You can always find the most recent version on the MindMed website. If substantial changes are made, we will try to provide at least a 30-day notice prior to any changes taking effect. What constitutes a substantial change will be determined at our sole discretion. By continuing to access or use our Service after those revisions become effective, you agree to be bound by the revised terms. If you do not agree to the new terms, please stop using the Services.
2. The Privacy Policy only covers data processing carried out by MindMed. The Privacy Policy does not address, and MindMed is not responsible for, the privacy practices of any other parties.
3. MindMed does not knowingly collect or ask for information from people under the age of 18. If you are such a person, please do not use our service or send us your information. Information that we learn is collected from a person under the age of 18 without verified parental consent is deleted.

1. Who is the Controller of your data?

1. Your data are being collected and processed by **Mind Medicine Inc.**, a Delaware corporation ("MindMed", "we", "us" or "our").
2. To learn more about data management or if you have any other questions, please contact us at mindmed@songacresquare.com

2. What data is processed?

We may collect the following types of information about you:

2.1. Personal Identifiable Information ("PII")

Through the Services MindMed may collect and process information that can be used to identify or contact you as an individual known as your PII, including but not limited to:

- name
- email address
- country of residence
- and other PI provided by you voluntarily when you use our Services.

2.2. Technical Information

2.2.1. MindMed and/or our authorised external service providers may automatically collect technical data when you visit or interact with our Services. Technical data may include, in particular:

- the URL of the site visited before using our Service
- the time and date of user visits
- IP address
- the browser name and type
- the type of computer or device accessing our Service
- time spent on the Service and other similar technical information

In a limited number of cases it is possible to use technical data and identify you as an individual, thus making them PII; however, we never use technical data to identify you as an individual.

2.2.2. MindMed use technical data to:

- Provide, operate, and maintain our Site
- Improve, personalize, and expand our Site
- Understand and analyze how you use our Site
- Develop new products, services, features, and functionality
- Communicate with you, either directly or through one of our partners, including for customer service

3. Cookies

3.1. What are cookies?

3.1.1. To make our Services work correctly, we sometimes place small data files called cookies and similar technologies on your device.

3.1.2. A cookie is a small text file that the Service saves on your device when you visit it. Session-based cookies last only while your browser is open and are automatically deleted when you close your browser. Permanent cookies last until you or your browser delete them or until their expiry.

3.2. How do we use cookies?

3.2.1. We use our session-based and also permanent functional cookies which enable the Site to remember your actions and preferences (e.g., to remember that you are logged in) so you don't have to keep re-entering them whenever you come back to the Site or browse from one page to another.

3.2.2. We also use cookies for analytics purposes to personalise your experience and to improve our Services.

3.3. Which cookies do we use?

3.3.1. We use the following cookies:

- **_ga:** The **_ga** cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. This cookie lasts for 2 years.
- **_gid:** The **_gid** cookie stores information on how visitors use a website, while also creating an analytics report of the Site's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously. This cookie lasts for 1 day.
- **_gat_gtag_UA_159451690_1** This cookie is set by Google to distinguish users and lasts for 1 minute.
- **XSRF-TOKEN:** This cookie is set by Wix and is used for security purposes. It lasts for 1 year.

3.4. How can you control cookies?

3.4.1. MindMed informs you about the use of cookies on your device when you visit our Site for the first time and, if applicable, we ask for your consent to use the cookies. The cookies will not be used for any purposes other than the ones stated above. Later, you may choose to accept or refuse cookies by selecting the appropriate settings in your browser.

3.4.2. As mentioned above, in some cases MindMed also may use cookies provided by third-parties (service providers). The list of such third-parties cookies of which you might encounter through our service is listed below. We are not responsible for third-party sites and their privacy practices. These companies collect and use this information under their own privacy policies and are responsible for their practices concerning cookies.

4. What are the purposes and legal basis for processing your PII?

4.1. MindMed process your PII in order to:

4.1.1. Provide our services to you

This purpose includes mainly the following processing activities:

- informing you about updates and new features of our Service;
- notifying you about updates of our terms & conditions of this Privacy Policy;
- responding to you in relation to any queries you may have with respect to our Services;

We process the email address, payment information and other data provided by you voluntarily when you use our Service.

4.1.2. Market our services

MindMed may market our current or future Services if you subscribe to our newsletter on our Site and by doing so, you provide us your consent with the processing of your email address for the marketing purposes.

There are several ways you can stop direct marketing communications from us:

- click the "Unsubscribe from newsletter" link in any email communication that we send you. We will then stop any further newsletter emails; or
- withdraw your consent through media@mindmed.co

4.1.3. Improve our services

This purpose includes the following processing activities using technical information:

- to influence current and future features;
- to prevent and detect security flaws and user interface issues.

4.1.4. Process an application as part of MindMed's recruitment

During our application process we may collect and process PII including, but not limited to, the applicant's:

- names
- photograph
- contact details
- professional background
- or any other PII contained in their CV

We also may be required to carry out a background check through a third party after notifying the applicant.

5. Who are recipients of your PII?

5.1. MindMed does not share your PII with any recipients outside of MindMed unless one of the following circumstances applies:

5.1.1. It is necessary for the compliance with our obligations towards you

To the extent that our external service providers (sub-processors) need access to your PII to help us perform our Services for you, we have taken the appropriate contractual and organizational measures to ensure that your PII are processed in accordance with all

have taken the appropriate technical and organisational measures to ensure that your PII is processed in accordance with applicable laws and regulations.

Below is a non-exclusive list of our sub-processors:

[LIST OF SUB-PROCESSORS IF APPLICABLE]

- Greenhouse Software Inc. (U.S.)
- Intuit Inc. (U.S.)
- MailChimp (U.S.)

The list of external service providers we use may change from time to time as we change or remove some of the providers listed above and/or put in place other providers to assist us in providing the Services.

5.1.2. It is necessary for legal reasons

MindMed may share your PII with recipients outside of MindMed if we have a good-faith belief that access to and use of your PII is reasonably necessary to: (i) meet any applicable law, regulation, and/or court order; (ii) detect, prevent, or otherwise address fraud, security or technical issues; and/or (iii) protect the interests, properties or safety of MindMed, our users or the public as far as in accordance with the law. When possible, we will inform you about such processing.

6. Where do we transfer your data to?

6.1. MindMed's Services are governed by and operated in, and in accordance with the laws of, the United States, and are intended for the enjoyment of residents of the United States. If you use our Services, or otherwise provide us with your PII, from outside the United States, you acknowledge and agree that your PII may be transmitted outside your resident jurisdiction. In particular, please note that your PII is stored and processed in the United States.

6.2. If we are involved in a merger, acquisition or other reorganisation, your information may be transferred as part of that deal. We will notify you (for example, via a message to the email address associated with your account) of any such deal and outline your choices in that event.

7. What is the storage period?

7.1. MindMed stores your PII only if it is legally permitted and necessary for the purposes for which the data were collected, or we are legally obliged to do so.

8. California Consumer Privacy Act Notice

8.1. If you are a California resident, California Civil Code Section 1798.83 permits you to request information regarding the disclosure of your PII to third parties for their direct marketing purposes. Moreover, you have the right to restrict the sharing of your PII and with our affiliates (companies we own or control) and outside companies with whom we do business.

8.2. MindMed is aware of your rights afforded to California residents under the California Consumer Privacy Act (the "CCPA"). Even though the CCPA does not apply to us now, we are ready to protect your PII and give you an option to exercise your right under CCPA once it becomes applicable.

8.3. To contact us with questions about our rights under California privacy laws email us at mindmed@longacresquare.com

9. What are your rights?

9.1. Right of access – MindMed offers you access to your PII we process. This means you can contact us and request from us a confirmation whether or not your PII are being processed and if so, you have the right to request access to your data, which we will provide to you in the form of a so-called "registry" (stating, in particular, purposes, categories of PII, categories of recipients of PII, storage periods or criteria for determining storage periods).


9.2. Right to erasure – You may also ask us to erase your PII from our systems. We will comply with such requests unless we have a legitimate ground to not delete your PII.

9.3. Right to restriction of processing -You may request us to restrict certain processing of your PII. If you restrict certain processing of your PII, this may lead to fewer possibilities to use our Services and Site.

9.4. How to use your rights -You may exercise your rights above, free of charge, in writing by sending a letter or email at mindmed@longacresquare.com . We may require confirmation of your identity depending on your request.

10. Is your data secured?

10.1. MindMed takes all reasonable, appropriate security measures to protect our customers from unauthorised access to or unauthorised alteration, disclosure or destruction of PII we hold. Measures include, where appropriate, encryption, firewalls, secure facilities and access rights systems. Should, despite the security measures, a security breach occur that is likely to have negative effects to your privacy, we will inform you about the breach as soon as reasonably possible. If you have any questions, feel free to contact us at mindmed@longacresquare.com.



[DISCLAIMER](#)

[PRIVACY POLICY](#)